JP2023544201A5 - - Google Patents

Info

Publication number
JP2023544201A5
JP2023544201A5 JP2023521092A JP2023521092A JP2023544201A5 JP 2023544201 A5 JP2023544201 A5 JP 2023544201A5 JP 2023521092 A JP2023521092 A JP 2023521092A JP 2023521092 A JP2023521092 A JP 2023521092A JP 2023544201 A5 JP2023544201 A5 JP 2023544201A5
Authority
JP
Japan
Prior art keywords
kit
composition
parts according
immune checkpoint
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077777 external-priority patent/WO2022074152A1/en
Publication of JP2023544201A publication Critical patent/JP2023544201A/ja
Publication of JP2023544201A5 publication Critical patent/JP2023544201A5/ja
Pending legal-status Critical Current

Links

JP2023521092A 2020-10-08 2021-10-07 がんを処置するための免疫療法 Pending JP2023544201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20200835.5 2020-10-08
EP20200835 2020-10-08
PCT/EP2021/077777 WO2022074152A1 (en) 2020-10-08 2021-10-07 Immunotherapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023544201A JP2023544201A (ja) 2023-10-20
JP2023544201A5 true JP2023544201A5 (enExample) 2024-09-13

Family

ID=72811720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521092A Pending JP2023544201A (ja) 2020-10-08 2021-10-07 がんを処置するための免疫療法

Country Status (10)

Country Link
US (1) US20230372384A1 (enExample)
EP (1) EP4225374A1 (enExample)
JP (1) JP2023544201A (enExample)
KR (1) KR20230084476A (enExample)
CN (1) CN116348142A (enExample)
AU (1) AU2021357354A1 (enExample)
CA (1) CA3192963A1 (enExample)
IL (1) IL301906A (enExample)
MX (1) MX2023004101A (enExample)
WO (1) WO2022074152A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320618A (en) * 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
AU2023376540A1 (en) * 2022-11-07 2025-05-15 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
JP2025540912A (ja) * 2022-11-07 2025-12-17 ターグイミューン セラピューティクス アクチエンゲゼルシャフト ポリエチレンイミン及びポリエチレングリコールを含む標的化された線状コンジュゲート並びにそれを含むポリプレックス

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6569896B2 (en) 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20030022868A1 (en) 2001-06-25 2003-01-30 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
KR20030043780A (ko) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
US7148250B2 (en) 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
JP5113979B2 (ja) 2002-02-28 2013-01-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
AU2003241583B2 (en) 2002-06-17 2009-05-21 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1562594A4 (en) 2002-10-15 2008-12-17 Univ Tennessee Res Foundation SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
EP2457892A1 (en) 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US20040167103A1 (en) 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
US20060258628A1 (en) 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2512459A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
US10278991B2 (en) * 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
WO2016183447A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
WO2017044936A1 (en) 2015-09-11 2017-03-16 Pfizer Inc. Methods of controlling morphology of polymeric nanoparticles
DK3378482T5 (da) 2015-11-19 2024-09-30 Univ Nagoya City Public Univ Corp Formulering til administration af antitumorlægemiddel
WO2017089942A1 (en) 2015-11-25 2017-06-01 Pfizer Inc. Therapeutic nanoparticles comprising an antibiotic and methods of making and using same
EP3688008A1 (en) * 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
WO2020077077A1 (en) * 2018-10-10 2020-04-16 The Regents Of The University Of California Combination immunotherapies
SG11202109274TA (en) * 2019-04-03 2021-10-28 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer

Similar Documents

Publication Publication Date Title
ES3059876T3 (en) Biologically active cluster of molecules
Salameh et al. Polymer‐mediated gene therapy: Recent advances and merging of delivery techniques
He et al. pH-sensitive drug-delivery systems for tumor targeting
RU2016146389A (ru) Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
Wang et al. A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios
Chen et al. Polyplex micelle installing intracellular self-processing functionalities without free catiomers for safe and efficient systemic gene therapy through tumor vasculature targeting
York et al. Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers
Wang et al. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis
ES2661461T3 (es) Polímeros de polioxazolina y métodos para su preparación, conjugados de estos polímeros, y sus usos médicos
Kasala et al. Utilizing adenovirus vectors for gene delivery in cancer
Nuhn et al. New Perspectives of HPMA‐based Copolymers Derived by Post‐Polymerization Modification
KR100953917B1 (ko) 항체의 Ｆｃ 영역에 특이적 결합능을 가지는 리포펩타이드 및 그를 포함하는 항원 인지형 지질 나노입자
FI3283521T3 (fi) Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan
Pan et al. Monoclonal antibody 2C5-modified mixed dendrimer micelles for tumor-targeted codelivery of chemotherapeutics and siRNA
Wang et al. A photoresponsive antibody–siRNA conjugate for activatable immunogene therapy of cancer
Jiang et al. Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
Liu et al. An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy
JP2011511773A5 (enExample)
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
Sheehy et al. STING-activating polymer–drug conjugates for cancer immunotherapy
JP2011529492A5 (enExample)
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
JP2017521090A5 (enExample)
Li et al. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy
JP2014521661A5 (enExample)